Etripamil is a self-administered nasal spray designed to be a rapid-response therapy for episodic cardiovascular conditions. Positive topline data were announced from a phase 3 trial evaluating the ...

MONTREAL and CHARLOTTE, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug Application (NDA) for etripamil to the ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

- Recently completed NODE-301 and ongoing NODE-301B studies can be used as two efficacy studies supporting a future NDA submission (target p-values of <0.05) - - NODE-301B, renamed the RAPID study, ...

– Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) – – Etripamil showed rapid conversion of SVT to SR during the first 45 minutes ...

MONTREAL and CHARLOTTE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...

MONTREAL and CHARLOTTE, N.C., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S.

MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response ...

MONTREAL and CHARLOTTE, N.C., April 30, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ...